Toward a model of memory enhancement in schizophrenia: Glucose administration and hippocampal function

Schizophrenia Bulletin

Volumn 34, Issue 1, 2008, Pages 93-108

  Stone, William S ^a,b   Seidman, Larry J ^a,b,c  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antipsychotic medication; Cognitive enhancement; Medial temporal lobe

Indexed keywords

ADRENALIN; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; DONEPEZIL; DOPAMINE UPTAKE INHIBITOR; GLUCOSE; GUANFACINE; MIANSERIN; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; ONDANSETRON; OXOTREMORINE; PHYSOSTIGMINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR;

BRAIN FUNCTION; BRAIN REGION; COGNITION; COGNITIVE DEFECT; CORRELATION ANALYSIS; DECLARATIVE MEMORY; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TEMPORAL LOBE; VERBAL MEMORY;

CHILD; COGNITION DISORDERS; GLUCOSE; HIPPOCAMPUS; HUMANS; MEMORY DISORDERS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TEMPORAL LOBE; VERBAL BEHAVIOR;

EID: 37149004876     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm041     Document Type: Review

References (250)

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry. 1996;153:321-330.
2. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
3. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002;52:969-971.
4. Fujii DE, Wylie AM. Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res. 2002;59:219-223.
5. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am. 2003;26:25-40.
6. Harvey PD, Keefe RSE. Cognition and the new antipsychotics. J Adv Schizophr Brain Res. 1998;1:2-8.
7. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol. 1998;18(suppl):12s-19s.
8. Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry. 2001;49:374-384.
9. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry. 1999;60(suppl 12):24-29.
10. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
11. Hyman SE, Fenton WS. What are the right targets for psychopharmacology? Science. 2003;299:350-351.
12. Stone WS, Seidman LJ, Wojcik JD, Green AI. Glucose effects on cognition in schizophrenia. Schizophr Res. 2003;62:93-103.
13. Harvey PD, Geyer MA, Robbins TW, Krystal JH. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology. 2003;169:213-214.
14. Broadbent NJ, Clark RE, Zola S, Squire LR. The medial temporal lobe and memory. In: Squire LR, Schacter DL, eds. Neuropsychology of Memory. New York, NY: The Guilford Press; 2002:3-23.
15. Seidman LJ. Schizophrenia and brain dysfunction: an integration of recent neurodiagnostic findings. Psychol Bull. 1983;94:195-238.
16. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull. 1984;10:300-312.
17. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618-624.
18. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
19. Seidman LJ, Stone WS, Jones R, Harrison RH, Mirsky AF. Cognitive effects of schizophrenia and temporal lobe epilepsy on memory. J Int Neuropsychol Soc. 1998;4:342-352.
20. Kremen WS, Seidman LJ, Faraone SV, Toomey R, Tsuang MT. The paradox of normal neuropsychological function in schizophrenia. J Abnorm Psychol. 2000;109:743-752.
21. Seidman LJ, Faraone SV, Goldstein JM, et al. Left hippocampal volume as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric study of nonpsychotic first-degree relatives. Arch Gen Psychiatry. 2002;59:839-849.
22. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
23. Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol. 2005;60:229-242.
24. Bromley E. A collaborative approach to targeted treatment development for schizophrenia: evaluation of the NIMH-MATRICS project. Schizophr Bull. 2005;31:954-961.
25. Auerbach J, Hans S, Marcus J. Neurobehavioral functioning and social behavior of children at risk for schizophrenia. Isr J Psychiatry Relat Sci. 1993;30:40-49.
26. Mirsky AF, Yardley SL, Jones BP, Walsh D, Kendler KS. Analysis of the attention deficit in schizophrenia: a study of patients and their relatives in Ireland. J Psychiatr Res. 1995;29:23-42.
27. Erlenmeyer-Kimling L, Rock D, Roberts SA, et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am J Psychiatry. 2000;157:1416-1422.
28. Erlenmeyer-Kimling L. Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am J Med Genet (Neuropsychiatr Genet). 2000;97:65-71.
29. Mirsky AF, Duncan CC. A neuropsychological perspective on vulnerability to schizophrenia: lessons from high-risk studies. In: Stone WS, Faraone SV, Tsuang MT, eds. Early Clinical Intervention and Prevention in Schizophrenia. Totowa, NJ: Humana Press; 2004:115-132.
30. Stone WS, Faraone SV, Seidman LJ, Olson EA, Tsuang MT. Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. J Child Adolesc Psychopharmacol. 2005;15:403-417.
31. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia. Schizophr Bull. 1992;18:437-448.
32. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.
33. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
34. Sweeney JA, Haas GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. Psychiatry Res. 1991;38:63-76.
35. Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev. 2003;13:43-77.
36. Levin S, Yurgelun-Todd D, Craft S. Contributions of clinical neuropsychology to the study of schizophrenia. J Abnorm Psychol. 1989;98:341-356.
37. Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit? Am J Psychiatry. 1994;151:40-48.
38. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 2004;72:21-28.
39. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry. 1999;156:1358-1366.
40. Beatty WW, Jocic Z, Monson N, Staton D. Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1993;181:448-453.
41. Gold J, Randolph C, Carpenter C, Goldberg T, Weinberger D. Forms of memory failure in schizophrenia. J Abnorm Psychol. 1992;101:487-494.
42. Paulsen JS, Heaton RK, Sadek JR, et al. The nature of learning and memory impairments in schizophrenia. J Int Neuropsychol Soc. 1995;1:88-99.
43. Heaton R, Paulsen JS, McAdams LA, et al. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry. 1994;51:469-476.
44. Seidman LJ, Cassens GP, Kremen WS, Pepple JR. Neuropsychology of schizophrenia, in clinical syndromes in adult neuropsychology. In: White RF, ed. The Practitioner's Handbook. Amsterdam: Elsevier Science Publishers B.V., 1992:381-450.
45. Brebion G, Amador X, Smith MJ, Gorman JM. Mechanisms underlying memory impairment in schizophrenia. Psychol Med. 1997;27:383-393.
46. Weiss AP, Heckers S. Neuroimaging of declarative memory in schizophrenia. Scand J Psychol. 2001;42:239-250.
47. Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34:369-374.
48. Joyce E. Origins of cognitive dysfunction in schizophrenia: clues from age at onset. Br J Psychiatry. 2005;86:93-95.
49. Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Lyons MJ, Tsuang MT. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J Abnorm Psychol. 1995;104:286-304.
50. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a four-year follow-up study. J Abnorm Psychol. 1999;108:176-181.
51. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading. Biol Psychiatry. 2000;48:120-126.
52. Kremen WS, Hoff AL. Neurocognitive deficits in the biological relatives of individuals with schizophrenia. In: Stone WS, Faraone SV, Tsuang MT, eds. Early Clinical Intervention and Prevention with Schizophrenia. Totowa, NJ: Humana Press, 2004:133-158.
53. Eichenbaum H. The hippocampal system and declarative memory in humans and animals: experimental analysis and historical origins. In: Schacter D, Tulving E, eds. Memory Systems. Cambridge, Mass: MIT Press; 1994:147-201.
54. Eichenbaum H. Memory representations in the parahippocampal region. In: Witter M, Wouterlood F, eds. The Parahippocampal Region: Organization and Role in Cognitive Function. New York, NY: Oxford University Press; 2002:165-184.
55. Freedman R, Adams CE, Adler LE, et al. Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet (Neuropsychiatr Genet). 2000;97:58-64.
56. Davison K, Bagley C. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: a review of the literature. Br J Psychiatry. 1969;4:113-184.
57. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001;49:1-52.
58. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry. 1992;149:890-897.
59. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology. 2004;174:151-162.
60. Weinberger DR. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry. 1999;45:395-402.
61. Lawrie SM, Whalley HC, Abukmeil SS, et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry. 2001;49:811-823.
62. Seidman LJ, Pantelis C, Keshavan MS, et al. A review and a new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a MRI morphometric family study of the parahippocampal gyrus. Schizophr Bull. 2003;29:803-808.
63. Seidman LJ, Wencel HE, McDonald C, Murray RM, Tsuang MT. Neuroimaging studies of nonpsychotic first-degree relatives of people with schizophrenia. In: Stone WS, Faraone SV, Tsuang MT, eds. Early Clinical Intervention and Prevention in Schizophrenia. Totowa, NJ: Humana Press; 2004:179-210.
64. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry. 1998;44:88-97.
65. Bogerts B. The temporolimbic system theory of positive schizophrenic symptoms. Schizophr Bull. 1997;23:423-435.
66. Kraepelin E. Dementia Praecox and Paraphrenia. Huntington, New York, NY: Robert Krieger; 1919/1971.
67. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23:223-239.
68. Rajarethinam R, DeQuardo JR, Miedler J, et al. Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology. Psychiatry Res: Neuroimaging Sect. 2001;108:79-87.
69. Rajarethinam R, Sahni S, Rosenberg DR, Keshavan MS. Reduced superior temporal gyrus volume in young offspring of patients with schizophrenia. Am J Psychiatry. 2004;161:1121-1124.
70. Beyer JL, Kuchibhatla M, Payne ME, et al. Hippocampal volume measurement in older adults with bipolar disorder. Am J Geriatr Psychiatry. 2004;12:613-620.
71. Blumberg HP, Kaufman J, Martin A, et al. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry. 2003;60:1201-1208.
72. Videbach P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957-1966.
73. Brambilla P, Harenski K, Nocoletti M, et al. MRI investigation of temporal lobe structures in bipolar patients. J Psychiatr Res. 2003;37:287-295.
74. Nelson M, Saykin A, Flashman L, Riordan H. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry. 1998;55:433-440.
75. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry. 2005;57:252-260.
76. Schacter DL. Memory, amnesia and frontal lobe dysfunction. Psychobiology. 1987;15:21-36.
77. Wheeler MA, Stuss DT, Tulving E. Frontal lobe damage produces episodic memory impairment. J Int Neuropsychol Soc. 1995;1:525-536.
78. Wagner AD. Cognitive control and episodic memory: contributions from prefrontal cortex. In: Squire LR, Schacter DL, eds. Neuropsychology of Memory. New York, NY: The Guilford Press; 2002:174-192.
79. Goldman-Rakic P. Cerebral cortical mechanisms in schizophrenia. Neuropsychopharmacology. 1994;10:22S-27S.
80. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1998;1:318-323.
81. Barch DM, Csernansky JG, Conturo T, Snyder AZ. Working and long-term memory deficits in schizophrenia: is there a common prefrontal mechanism? J Abnorm Psychol. 2002;111:478-494.
82. Berman KF. Functional neuroimaging in schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:745-756.
83. Weiss AP, Schacter DL, Goff DC, Rausch SL, Alpert NM, Heckers S. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry. 2003;53:48-55.
84. Seidman LJ, Yurgelun-Todd D, Kremen WS, et al. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry. 1994;35:235-246.
85. Davidson PSR, Troyer AK, Moscovitch M. Frontal lobe contributions to recognition and recall: linking basic research with clinical evauation and remediation. J Int Neuropsychol Soc. 2006;12:210-223.
86. Stuss DT, Alexander MP, Shallice T, et al. Multiple frontal systems controlling response speed. Neuropsychologia. 2005;43:396-417.
87. Braver TS, Barch DM. A theory of cognitive control, aging, cognition and neuromodulation. Neurosci Biobehav Rev. 2002;26:809-817.
88. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 1990;16:477-499.
89. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition: opening a closed book. Biol Psychiatry. 2004;55:1013-1022.
90. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W. The impact of atypical antipsychotic medications on longterm memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol. 2006;20:335-346.
91. Stip E. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 1996;41:S35-S40.
92. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201-222.
93. Meltzer H, McGurk S. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
94. Kern R, Green M, Marshall B, et al. Risperidone vs. haloperidol on secondary memory: can newer antipsychotic medications aid learning? Schizophr Bull. 1999;25:223-232.
95. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change during early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249-258.
96. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
97. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzepine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. 2003;169:404-411.
98. Weickert CS, Kleinman JE. The neuroanatomy and neurochemistry of schizophrenia. Psychiatr Clin North Am. 1998;21:57-75.
99. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard settings. J Clin Psychiatry. 2003;64:524-531.
100. Keefe RSE, Seidman LJ, Christensen BK, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 2006;59:97-105.
101. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Wienberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination confounds. Neuropsychopharmacology. 2003;28:1491-1500.
102. Meltzer HY. Mechanisms of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkens; 2002:819-831.
103. Lenzi A, Maltini E, Poggi E, Fabrizio L, Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol. 2003;26:317-321.
104. Buchanan RW, Summerfelt A, Tek C, Gold J. An openlabeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res. 2003;59:29-33.
105. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349-357.
106. Tual N, Yazc KM, Yacolu AE, Gogus A. A double-blind, placebo-controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol. 2004;7:117-123.
107. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology. 2005;181:358-353.
108. Kumari V, Aasen I, Ffytche D, Williams SCR, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage. 2006;29:545-556.
109. Levkovitz Y, Ophir-Shaham O, Bloch Y, Treves I, Fennig S, Grauer E. Effect of L-tryptophan on memory in patients with schizophrenia. J Nerv Ment Dis. 2003;191:568-573.
110. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull. 2005;65:291-295.
111. Poyurovsky M, Koren D, Gonopolsky I, et al. Effect of 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003;13:123-128.
112. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology. 2004;29:1363-1373.
113. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology. 2001;25:402-409.
114. Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr. 2004;9:350-355.
115. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 1991;148:78-84.
116. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991;11:1907-1917.
117. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005;77:43-58.
118. Hagan JJ, Jones DNC. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull. 2005;31:830-853.
119. Gemperle AY, McAllister KH, Olpe H-R. Differential effects of iloperidone, clozapine and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology. 2003;169:354-364.
120. Terranova J-P, Chabot C, Barnoiun M-C, Depoortere R, Briebel G, Scatton B. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agaonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology. 2005;181:134-144.
121. White NM, McDonald RJ. Multiple parallel memory systems in the brain of a rat. Neurobiol Learn Mem. 2002;77:125-184.
122. Poldrack RA, Packard MG. Competition among multiple memory systems: converging evidence from animal and human brain studies. Neuropsychologia. 2003;41:245-251.
123. Gold PE. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem. 2003;80:194-210.
124. Gold PE. Coordination of multiple memory systems. Neurobiol Learn Mem. 2004;82:230-242.
125. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Rev. 2003;41:268-287.
126. Stone WS, Walser B, Gold SD, Gold PE. Scopolamine- and morphine-induced impairments of spontaneous alternation in rats: reversal with glucose and with cholinergic and adrenergic agonists. Behav Neurosci. 1991;105:264-271.
127. Stone WS, Rudd RJ, Gold PE. Glucose and physostigmine effects on morphine- and amphetamine-induced increases in locomotor activity in mice. Behav and Neural Biol. 1990;54:146-155.
128. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380-1386.
129. Cohen NJ, Eichenbaum H. Memory, Amnesia and the Hippocampal System. Cambridge, Mass: MIT Press; 1993.
130. Poldrack RA, Rodriguez P. How do memory systems interact? Evidence from human classification learning. Neurobiol Learn Mem. 2004;82:324-332.
131. Gabriele A, Packard MG. Evidence of a role for multiple memory systems in behavioral extinction. Neurobiol Learn Mem. 2006;85:289-299.
132. Whalley LJ, Deary IJ, Appleton CL, Starr JM. Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev. 2004;3:369-382.
133. Stern Y, Habeck C, Moeller J, et al. Brain networks associated with cognitive reserve in healthy young and old adults. Cereb Cortex. 2005;15:394-402.
134. Pai MC, Tsai JJ. Is cognitive reserve applicable to epilepsy? The effect of educational level on the cognitive decline after onset of epilepsy. Epilepsia. 2005;46(suppl 1):7-10.
135. Le Carret N, Auriacombe S, Letenneur L, Bergua V, Dartigues JF, Fabrigoule C. Influence of education on the pattern of cognitive deterioration in AD patients: the cognitive reserve hypothesis. Brain Cogn. 2005;57:120-126.
136. Springer MV, McIntosh AR, Winocur G, Grady CL. The relations between brain activity during memory tasks and years of education in young and older adults. Neuropsychology. 2005;19:181-192.
137. Gold PE. Glucose modulation of memory storage processing. Behavior Neural Biol. 1986;45:342-349.
138. Gold PE, Vogt J, Hall JL. Glucose effects on memory: behavioral and pharmacological characteristics. Behav Neural Biol. 1986;46:145-155.
139. Messier C, White NM. Contingent and non-contingent actions of sucrose and saccharin reinforcers: effects on taste preference and memory. Physiol Behav. 1984;32:195-203.
140. Messier C, White NM. Memory improvement by glucose, fructose and two glucose analogs: a possible effect of peripheral glucose transport. Behav Neural Biol. 1987;48:104-127.
141. Gold PE, Stone WS. Neuroendocrine effects on memory in aged rodents and humans. Neurobiol Aging. 1988;9:709-717.
142. Gold PE. Role of glucose in regulating the brain and cognition. Am J Clin Nutr. 1995;61(suppl):987S-995S.
143. Messier C, Desrochers A, Gagnon M. Effect of glucose, glucose regulation and word imagery value on human memory. Behav Neurosci. 1999;113:431-438.
144. Korol DL. Enhancing cognitive function across the life span. Ann N Y Acad Sci. 2002;959:167-179.
145. Messier C. Glucose improvement of memory: a review. Eur J Pharmacol. 2004;490:33-57.
146. Hall JL, Gonder-Frederick LA, Chewning WW, Silveira J, Gold PE. Glucose enhancement of performance on memory tests in young and aged humans. Neuropsychologia. 1989;27:1129-1138.
147. Manning CA, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging. 1993;14:523-528.
148. Craft S, Zallen G, Baker LD. Glucose and memory in mild senile dementia of the Alzheimer's type. J Clin Exp Neuropsychol. 1992;14:253-267.
149. Messier C, Gagnon M, Knott V. Effect of glucose and peripheral glucose regulation on memory in the elderly. Neurobiol Aging. 1997;18:297-304.
150. Manning CA, Honn VJ, Stone WS, Jane JS, Gold PE. Glucose effects on adults with Down's syndrome. Neuropsychology. 1998;12:479-484.
151. Ragozzino ME, Gold PE. Glucose injections into the medial septum reverse the effects of intraseptal morphine infusions on hippocampal acetylcholine output and memory. Neuroscience. 1995;68:981-988.
152. Stone WS, Rudd RJ, Gold PE. Glucose effects on scopolamine-and age-induced deficits in spontaneous alternation behavior and in regional [3H]2-deoxyglucose uptake in mice. Psychobiology. 1992;20:270-279.
153. Flint RW, Riccio D. Pretest administration of glucose attenuates infantile amnesia for passive avoidance conditioning in rats. Dev Psychobiol. 1997;31:207-216.
154. Flint RW, Riccio D. Post-training glucose administration attenuates forgetting of passive-avoidance conditioning in 18-day-old rats. Neurobiol Learn Mem. 1999;72:62-67.
155. Stone WS, Altman HJ, Arankowsky-Sandovaal G, Parekh PI, Hall JL, Gold PE. Prenatal exposure to alcohol in adult rats: relationships between sleep and memory deficits, and effects of glucose administration on memory. Brain Res. 1996;742:98-106.
156. Newcomer JW, Craft S, Fucetola R, et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull. 1999;25:321-335.
157. Fucetola R, Newcomer JW, Craft S, Melson AK. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res. 1999;88:1-13.
158. Parent MB, Varnhagen C, Gold PE. A memory-enhancing emotionally arousing narrative increases blood glucose levels in college students. Psychobiology. 1999;27:386-396.
159. Blake TM, Varnhagen CK, Parent MB. Emotionally arousing pictures increase blood glucose levels and enhance recall. Neurobiol Learn Mem. 2001;75:262-273.
160. Sunram-Lea SI, Foster JK, Durlach P, Perez C. Investigation into the significance of task difficulty and divided allocation of resources in the glucose memory facilitation effect. Psychopharmacology. 2002;160:387-397.
161. Manning CA, Hall JL, Gold PE. Glucose effects on memory and other neuropsychological tests in elderly humans. Psychol Sci. 1990;1:307-311.
162. Foster JK, Lidder PG, Sunram SI. Glucose and memory: fractionation of enhancement effects? Psychopharmacology. 1998;137:259-270.
163. Scholey AB, Harper S, Kennedy DO. Cognitive demand and blood glucose. Physiol Behav. 2001;73:585-592.
164. Benton D, Owens DS, Parker PY. Blood glucose influences memory and attention in young adults. Neuropsychologia. 1994;32:595-607.
165. Kennedy DO, Scholey AB. Glucose administration, heart rate and cognitive performance: effects of increasing mental effort. Psychopharmacology. 2000;149:63-71.
166. Meikle A, Riby LM, Stollery B. The impact of glucose ingestion and gluco-regulatory control on cognitive performance: a comparison of young and middle-aged adults. Hum Psychopharmacol. 2004;19:523-535.
167. Sunram-Lea SI, Foster JK, Durlach P, Perez C. Glucose facilitation of cognitive performance in healthy young adults: examination of the influence of fast-duration, time of day and pre-consumption plasma glucose levels. Psychopharmacology. 2001;157:46-54.
168. Sunram-Lea SI, Foster JK, Durlach P, Perez C. The effect of retrograde and anterograde glucose administration on memory performance in healthy young adults. Behav Brain Res. 2002;134:505-516.
169. Riby LM, Meikle A, Glover C. The effect of age, glucose ingestion and gluco-regulatory control on episodic memory. Age Ageing. 2004;33:483-487.
170. McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand in a spatial task. Proc Natl Acad Sci USA. 2000;97:2881-2885.
171. Ryan CM, Geckle M. Why is learning and memory dysfunction in type 2 diabetes limited to older adults? Diabetes/ Metab Res Rev. 2000;16:308-315.
172. Jacobson AM, Samson JA, Weinger K, Ryan CM. Diabetes, the brain, and behavior: is there a biological mechanism underlying the association between diabetes and depression? In: Dwyer DS, ed. Glucose Metabolism in the Brain. New York, NY: Academic Press; 2002:455-479.
173. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol. 1993;48:M117-M121.
174. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes. J Am Geriatr Soc. 1993;41:1305-1312.
175. Naor M, Steingruber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complications. 1997;11:40-46.
176. Craft S, Murphy C, Wemstrom J. Glucose effects on complex memory and nonmemory tasks: the influence of age, sex and glucoregulatory response. Psychobiology. 1994;22:95-105.
177. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia. 1995;38:1096-1102.
178. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care. 1998;21:398-402.
179. Kaplan RJ, Greenwood CE, Winocur G, Wolever T. Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. Am J Clin Nutr. 2000;72:835-836.
180. Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA. 2003;100:2019-2022.
181. Messier C, Tsiakas M, Gagnon M, Desrochers A, Awad N. Effect of age and glucoregulation on cognitive performance. Neurobiol Aging. 2003;24:985-1003.
182. Greenwood CE, Kaplan RJ, Hebblethwaite S, Jenkins DJ. Carbohydrate-induced memory impairment in adults with type-2 diabetes. Diabetes Care. 2003;26:1961-1966.
183. Stone WS, Wenk GL, Olton DS, Gold PE. Poor blood glucose regulation predicts sleep and memory deficits in normal aged rats. J Gerontol: Biol sci. 1990;45:B169-B173.
184. Awad N, Gagnon M, Desrochers A, Tsiakas M, Messier C. Impact of peripheral glucoregulation on memory. Behav Neurosci. 2002;116:691-702.
185. Gold PE. Glucose and age-related changes in memory. Neurobiol Aging. 2005;26 (Suppl 1):S60-S64.
186. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol. 2006;209:2304-2311.
187. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B. 1999;354:1155-1163.
188. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur Neuropsychopharmacol. 2004;490:97-113.
189. Gruetter R. Glycogen: the forgotten cerebral energy store. J Neurosci Res. 2003;74:179-183.
190. Gibbs ME, Anderson DG, Hertz L. Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens. Glia. 2006;54:214-222.
191. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin asart. Neuropsychopharmacology. 2007;32:239-243.
192. Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999;56:1135-1140.
193. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 2001;74:270-280.
194. Hall JL, Reilly RT, Cottrill KL, Stone WS, Gold PE. Phlorizin enhancement of memory in rats and mice. Pharmacol Biochem Behav. 1992;41:295-299.
195. Stefani MR, Gold PE. Intra-septal injections of glucose and glibenclamide attenuate galanin-induced spontaneous alternation deficits in the rat. Brain Res. 1998;813:50-56.
196. Stefani MR, Gold PE. Intra-hippocampal infusions of KATP channel modulators influence spontaneous alternation performance: relationships to acetylcholine release in the hippocampus. J Neurosci. 2001;21:609-614.
197. Seaquist ER, Damberg GS, Tkac I, Gruetter R. The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans. Diabetes. 2001;50:2203-2209.
198. Messier C, Durkin T, Mrabet O, Destrade C. Memory-improving action of glucose: indirect evidence for a facilitation of hippocampal acetylcholine synthesis. Behav Brain Res. 1990;39:135-143.
199. Ragozzino ME, Unick KE, Gold PE. Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA. 1996;93:4693-4698.
200. McNay E, Gold PE. Age-related differences in hippocampal extracellular fluid glucose concentration during behavioral testing and following systemic glucose administration. J Gerontol A Biol Sci Med Sci. 2001;56:B66-B71.
201. McNay EC, Canal CE, Sherwin RS, Gold PE. Modulation of memory with septal injections of morphine and glucose: effects on extracellular glucose levels in the hippocampus. Physiol Behav. 2006;87:298-303.
202. Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry. 1945;102:108-110.
203. Schimmelbusch W, Mueller P, Sheps J. The positive correlation between insulin resistance and duration of hospitalization in schizophrenia. Br J Psychiatry. 1971;118:429-436.
204. Mukherjee S, Roth S, Sandyk R, Schnur D. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res. 1989;29:17-27.
205. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58:108-111.
206. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299.
207. Lindenmayer J-P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999;156:1471.
208. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
209. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1:495.
210. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry. 2003;48:345-347.
211. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
212. Wright P, Sham PC, Gilvarry CM, et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr Res. 1996;20:261-267.
213. Gilvarry CM, Sham PC, Jones PG, et al. Family history of autoimmune diseases in psychosis. Schizophr Res. 1996;19:33-40.
214. Dynes JB. Diabetes in schizophrenia and diabetes in non-psychotic medical patients. Dis Nerv Syst. 1969;30:341-344.
215. Stone WS, Faraone SV, Su J, Tarbox SI, Van Eerdewegh P, Tsuang MT. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet (Neuropsychiatr Genet). 2004;127:5-10.
216. Elman I, Rott D, Green AI, et al. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology. 2004;176:369-375.
217. Schaefer C, Brown AS, Wyatt RJ, et al. Maternal prepregnant body mass and risk of schizophrenia in the offspring. Schizophr Bull. 2000;26:275-286.
218. Gungor N, Arslanian S. Pathophysiology of type 2 diabetes mellitus in children and adolescents: treatment implications. Treat Endocrinol. 2002;1:359-371.
219. Gunnell D, Rasmussen F, Fouskakis D, Tynelius P, Harrison G. Patterns of fetal and childhood growth and the development of psychosis in young males: a cohort study. Am J Epidemiol. 2003;158:291-300.
220. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes. N Engl J Med. 1994;331:1428-1436.
221. Tsuang MT, Stone WS, Faraone SV. Schizophrenia: a review of genetic studies. Harv Rev Psychiatry. 1999;7:185-207.
222. Gottesman II. Psychopathology through a life-span genetic prism. Am Psychol. 2001;56:864-878.
223. Henderson DC, Ettinger ER. Schizophrenia and diabetes. In: Dwyer DS, ed. Glucose Metabolism in the Brain. New York, NY.: Academic Press; 2002:481-501.
224. Faraone SV, Glatt SJ, Taylor L. The genetic basis of schizophrenia. In: Stone WS, Faraone SV, Tsuang MT, eds. Early Clinical Intervention and Prevention in Schizophrenia. Totowa, NJ: Humana Press; 2004:3-25.
225. Stone WS, Thermenos HW, Tarbox SI, Poldrack RA, Seidman LJ. Medial prefrontal and temporal lobe activation and memory following glucose ingestion: a pilot fMRI study. Neurobiol Learn Mem. 2005;83:54-64.
226. Baptista T, Kin N, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2001;35:207-219.
227. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71:239-257.
228. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res. 2006;84:1-14.
229. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry. 2000;48:1121-1132.
230. Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:913-922.
231. Roozendaal B. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology. 2000;25:213-238.
232. McGaugh JL. The amygdala regulates memory consolidation. In: Squire LR, Schacter DL, eds. Neuropsychology of Memory. New York, NY: The Guilford Press; 2002:437-449.
233. Stone WS, Manning CA, Gold PE. Relationships between circulating glucose levels and memory storage processes. In: Altman HJ, Altman BN, eds. Alzheimer's and Parkinson's Disease: Recent Advances in Research and Clinical Management. New York, NY: Plenum Press; 1989:167-189.
234. Plat L, Byrne MM, Sturis J, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996;270:E36-E42.
235. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
236. McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res. 2002;53:883-890.
237. Wenk G. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology. 1989;99:431-438.
238. Saller CF, Chiodo LA. Glucose suppresses basal firing and haloperidol-induced increases in the firing rate of central dopaminergic neurons. Science. 1980;210:1269-1271.
239. Saller CF, Kopin IJ. Glucose potentiates hapoperidol-induced catalepsy. Life Sci. 1981;29:2337-2341.
240. Lozovsky DB, Saller CF, Kopin IJ. Dopamine receptor binding is increased in diabetic rats. Science. 1981;214:1031-1033.
241. Lozovsky DB, Kopin IJ, Saller CF. Modulation of dopamine receptor supersensitivity by chronic insulin: implication in schizophrenia. Brain Res. 1985;343:190-193.
242. Levin BE. Glucose-regulated dopamine release from substantia nigra neurons. Brain Res. 2000;874:158-164.
243. Thermenos HW, Goldstein JM, Buka SL, et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res. 2005;74:179-194.
244. Seidman LJ, Thermenos HW, Poldrack RA, et al. Altered brain activation in dorsolateral prefrontal cortex in adolescents and young adults at genetic risk for schizophrenia: an fMRI study of working memory. Schizophr Res. 2006;85:58-72.
245. Gutniak M, Blomqvist G, Widen L, Stone-Elander S, Hamberger B, Grill V. D-[U-11C] glucose uptake and metabolism in the brain of insulin-dependent diabetic subjects. Am J Physiol. 1990;258:E805-E812.
246. Siever LJ, Koenigsberg HW, Harvey P, et al. Cognitive and brain function in schizotypal personality disorder. Schizophr Res. 2002;54:157-167.
247. Hazlett EA, Buchsbaum MS, Byrne W, et al. Three-dimensional analysis with MRI and PET of the size, shape and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry. 1999;156:1190-1199.
248. Buchsbaum MS, Nenadic I, Hazlett E, et al. Prefrontal and temporal metabolic rates in schizophrenia and schizotypal personality disorder. Biol Psychiatry. 2001;49:172S-173S.
249. Callicott JH, Straub RE, Pezawas L, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA. 2005;102:8627-8632.
250. Blasi G, Mattay VS, Bertolino A, et al. Effect of catechol-O- methyltransferase val58met genotype on attentional control. J Neurosci. 2005;25:5038-5045.